Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Cystinosis Indication Strategy Report 2026: CTNS, Trials and Deals
30 July 2026
2026 Cystinosis indication strategy covering epidemiology, CTNS biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Lowe syndrome Indication Strategy Report 2026: OCRL, Trials and Deals
30 July 2026
2026 Lowe syndrome indication strategy covering epidemiology, OCRL biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Autosomal recessive Alport syndrome Indication Strategy Report 2026: COL4A3, Trials and Deals
30 July 2026
2026 Autosomal recessive Alport syndrome indication strategy covering epidemiology, COL4A3 biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Alport syndrome X-linked Indication Strategy Report 2026: COL4A5, Trials and Deals
30 July 2026
2026 Alport syndrome X-linked indication strategy covering epidemiology, COL4A5 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Primary hyperoxaluria type 3 Indication Strategy Report 2026: HOGA1, Trials and Deals
30 July 2026
2026 Primary hyperoxaluria type 3 indication strategy covering epidemiology, HOGA1 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Thymidine kinase 2 deficiency Indication Strategy Report 2026: TK2, Trials and Deals
30 July 2026
2026 Thymidine kinase 2 deficiency indication strategy covering epidemiology, TK2 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Primary hyperoxaluria type 2 Indication Strategy Report 2026: GRHPR, Trials and Deals
30 July 2026
2026 Primary hyperoxaluria type 2 indication strategy covering epidemiology, GRHPR biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Coenzyme Q10 deficiency Indication Strategy Report 2026: COQ8A, Trials and Deals
30 July 2026
2026 Coenzyme Q10 deficiency indication strategy covering epidemiology, COQ8A biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Mitochondrial complex V deficiency Indication Strategy Report 2026: TMEM70, Trials and Deals
30 July 2026
2026 Mitochondrial complex V deficiency indication strategy covering epidemiology, TMEM70 biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Mitochondrial depletion syndrome Indication Strategy Report 2026: POLG, Trials and Deals
30 July 2026
2026 Mitochondrial depletion syndrome indication strategy covering epidemiology, POLG biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Pearson syndrome Indication Strategy Report 2026: mtDNA, Trials and Deals
30 July 2026
2026 Pearson syndrome indication strategy covering epidemiology, mtDNA biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Barth syndrome Indication Strategy Report 2026: TAZ, Trials and Deals
30 July 2026
2026 Barth syndrome indication strategy covering epidemiology, TAZ biology, active trials, transactions, unmet need, competition and market attractiveness.